Group 1 - The core product, Isupreglutide α, for treating pet diabetes has received formal acceptance for clinical trial application by the Ministry of Agriculture and Rural Affairs of China [1] - The stock price of the company surged, reaching a peak increase of 20%, trading at HKD 31 during the session [1] - The company plans to commence Phase I clinical trials in the first quarter of this year [1] Group 2 - The board believes that developing diabetes medication for pets has significant prospects due to increasing consumer willingness to spend on extending pet lifespans [1] - The board considers this research aligns with the company's long-term business development strategy and will establish a solid foundation for entering the pet pharmaceuticals market [1]
港股异动丨银诺医药一度飙升20%，新兽药临床试验申请获受理
Ge Long Hui·2026-02-05 07:02